Abstract
Magnesium is crucial for various cellular and enzymatic processes, yet it often is overlooked or underappreciated. Hypomagnesemia, a deficiency of magnesium in the blood, is a frequent problem in cancer patients and can lead to severe symptoms and morbidity. In this review, we provide an in-depth analysis of the physiology and regulation of magnesium, and signs and symptoms of hypomagnesemia in cancer patients. We also examine the causes and mechanisms of magnesium imbalances in cancer patients, specifically focusing on cancer-specific therapies that can lead to hypomagnesemia. Finally, we provide updates on the management of hypomagnesemia, including oral and parenteral supplementation, as well as the role of drugs in cases that are resistant to treatment. This review aims to raise awareness among health care providers caring for cancer patients about the significance of monitoring magnesium levels in cancer patients and function as a guide. Future clinical studies should focus on magnesium monitoring, its impact on cancer progression, and its potential for preventing acute kidney injury.
Original language | English (US) |
---|---|
Article number | 151347 |
Journal | Seminars in Nephrology |
Volume | 42 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2022 |
Keywords
- cisplatin
- electrolytes
- hypomagnesemia
- integrative oncology
- magnesium
- Onconephrology
- TRPM6
ASJC Scopus subject areas
- Nephrology